
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees Pharmaceuticals Inc has demonstrated remarkable revenue growth, with net product revenues increasing 140% to $607.6k in FY24 and continuing this upward trend with a 223% year-over-year growth to $438 thousand in Q3 FY25. The increased sales of ARAKODA, which saw a 14% rise in deliveries, highlights the company's successful commercialization efforts for its key therapies amidst a growing market demand. Additionally, with a favorable safety profile for tafenoquine, there are promising opportunities for expanded clinical applications and commercialization potential, further supporting a positive outlook for the company's financial performance.
Bears say
60 Degrees Pharmaceuticals Inc is experiencing a challenging financial landscape, primarily driven by depressed forward multiples attributed to market volatility and a significant cash burn associated with various stages of development programs. The company reported a gross loss of approximately $9,000 in Q3 FY24, contrasting sharply with the previous year's gross profit of $36,000 due to a one-time inventory write-off, indicating potential operational inefficiencies. Additionally, low visibility on regulatory approvals and the risk of dilution from financing, paired with diminishing product demand and emerging resistance to key treatments, contribute to a cautious outlook for the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares